NASDAQ:CUE Cue Biopharma Q3 2025 Earnings Report $25.51 -1.94 (-7.07%) Closing price 04:00 PM EasternExtended Trading$25.07 -0.44 (-1.74%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cue Biopharma EPS ResultsActual EPS-$63.00Consensus EPS -$90.00Beat/MissBeat by +$27.00One Year Ago EPSN/ACue Biopharma Revenue ResultsActual Revenue$2.15 millionExpected Revenue$2.29 millionBeat/MissMissed by -$141.00 thousandYoY Revenue GrowthN/ACue Biopharma Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time7:00AM ETUpcoming EarningsCue Biopharma's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Cue Biopharma Earnings HeadlinesCue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?September 26 at 7:17 AM | finance.yahoo.comCue Biopharma (NASDAQ:CUE) Stock Moved Down to "Strong Sell" by Wall Street ZenSeptember 26 at 1:13 AM | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 29 at 1:00 AM | InvestorPlace (Ad)Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOASeptember 21, 2026 | seekingalpha.comCue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug CandidateSeptember 21, 2026 | finance.yahoo.comCue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial ResultsSeptember 21, 2026 | finance.yahoo.comSee More Cue Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cue Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cue Biopharma and other key companies, straight to your email. Email Address About Cue BiopharmaCue Biopharma (NASDAQ:CUE) is a clinical-stage biotechnology company developing therapeutics that selectively activate and regulate antigen-specific T cells inside the body. Its approach is designed to direct the immune system toward cancer cells while potentially reducing the broad immune activation and toxicity associated with conventional immunotherapies. The company’s proprietary Immuno-STAT (Selective Targeting of Antigens for Remodeling of T cells) platform uses biologic molecules that combine peptide-major histocompatibility complex components with immune-modulating signals. Cue’s pipeline includes investigational treatments intended for oncology and immune-related diseases, including programs targeting tumor-associated antigens such as human papillomavirus 16 and Wilms tumor 1. Cue Biopharma is headquartered in Boston, Massachusetts, and focuses primarily on research, clinical development and strategic collaboration activities rather than commercialized products. Its lead programs have been evaluated in clinical studies for advanced cancers, including HPV16-positive malignancies and other solid tumors. The company is led by President and Chief Executive Officer Daniel R. Passeri.View Cue Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
